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Purpose: The purpose of this study was to examine
costs, resource use, adherence, and hypoglycemic
events among patients with type 2 diabetes mellitus
(T2DM) treated with increasing doses of 100-U/mL
(U-100) insulin regimens.
Methods: Data from Truven’s Health Analytics
Commercial Claims and Encounters database from
January 1, 2008, through January 31, 2011, were
used. Regressions were used to examine the associa-
tions among costs, resource use, adherence, and
receipt of a hypoglycemic event and index dose
of insulin. Speciﬁcally, general linear models with a
γ-distribution and log link were used to examine costs,
whereas logistic and negative binomial regressions
were used to examine resource use and hypoglycemic
events. All analyses controlled for patient character-
istics, preindex comorbidities, general health, use of
antidiabetic medications, and visits to an endocrino-
logist.
Findings: The study focused on 101,728 individuals
with T2DM who received an outpatient prescription
for U-100 insulin. In general, costs and resource use
are highest among patients treated with the highest
dose of insulin (4300 U/d). For example, all-cause
and diabetes-related hospitalizations and ofﬁce visits
were highest in the highest-dose cohort. Costs gen-
erally followed the same pattern. Patients who were
prescribed the lowest dose of insulin (10-100 U/d)
generally had higher all-cause or diabetes-related
inpatient and emergency department costs and re-
source use compared with those patients with an
index dose 4100 to 150, 4150 to 200, and 4200
to 300 U/d. There were generally no signiﬁcant*Current afﬁliation: Medtronic Inc, Fishers, Indiana
October 2015differences in rates of hypoglycemic events based on
index dose.
Implications: These results suggest signiﬁcant dif-
ferences in patient outcomes based on dosing of
insulin. Those patients with T2DM using insulin at
the highest and lowest dose ranges have the high-
est costs and resource use. (Clin Ther. 2015;37:2297–
2308) & 2015 The Authors. Published by Elsevier HS
Journals, Inc.
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INTRODUCTION
Diabetes mellitus is a highly prevalent, chronic con-
dition that can lead to severe complications, such as
kidney failure, lower-limb amputations, blindness,
heart disease, stroke, and early death.1,2 Currently in
the United States, 11.3% of the adult (Z20 years of
age) population has diabetes,1 and approximately
one-third of Americans are predicted to have this
diagnosis by the year 2050.3 The total cost of the
disease in the United States in 2012 was $245 billion,
comprising $176 billion in direct medical costs and
$69 billion in decreased productivity.4
Of all diabetes cases, approximately 5% are type 1
diabetes mellitus (T1DM) and 90% to 95% are type 2
diabetes mellitus (T2DM).2 Metformin therapy, in
combination with lifestyle interventions, is the ﬁrst
line of treatment for T2DM.5 However, individuals
with T2DM often require insulin treatment over time0149-2918/$ - see front matter
& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Clinical Therapeuticsbecause of the progressive loss of β-cell function.6
In 2011, an estimated 24.1% of US adults with
T2DM used insulin.7,8 Insulin therapy is the oldest
and most effective glucose-lowering treatment avail-
able,5 and patients with T2DM taking insulin soon
after the failure of oral antidiabetic therapy have a
greater likelihood of attaining the standard glycemic
control (hemoglobin A1c [HbA1c] o7%) relative to
those whose insulin treatment is delayed.9,10
Given the increasing use of insulin, as well as the
increasing prevalence of T2DM among young
adults,11 the present study sought to examine
associations between insulin dosing and outcomes
among the US working-age adult population with
T2DM. To this end, this retrospective study used a
medical insurance claims database to examine the
records of patients at varying doses of standard
strength (100 U/mL [U-100]) insulin. Outcomes of
interest included costs, resource use, adherence, and
hypoglycemic events.
METHODS
The Truven Health Analytics Marketscans Commer-
cial Claims and Encounters database provided the
data used in this retrospective analysis. Encompassing
a geographically diverse population of insured pa-
tients in the United States, the database contains
demographic characteristics and enrollment informa-
tion, as well as inpatient, outpatient, and prescription
drug claims. All data were fully compliant with the
Health Insurance Portability and Accountability Act.
This study examined the associations between a
patient’s highest mean daily dose of insulin for 90
days and direct medical costs, resource use, adherence,
and probability of a hypoglycemic event. The mean
daily dose during a 90-day period was calculated
based on the quantity of insulin prescribed during a
90-day period and the number of days of insulin
covered by the prescription. The use of a 90-day
period was chosen because HbA1c measurement gen-
erally measures the amount of glucose that binds to
hemoglobin during a 3-month period,12 as well as the
fact that the American Diabetes Association states that
HbA1c measurement “approximately every 3 months
determines whether a patient’s glycemic targets have
been maintained.”13
The insulin was from pens or vials that contained
U-100 insulin, which is the standard strength of
nonconcentrated insulin distributed in the United2298States,14–16 and the total daily dose encompassed
basal (intermediate or long-acting insulin), bolus
(rapid or short-acting insulin), or premixed formula-
tions (of basal and bolus). The highest mean daily
dose found in any 90-day timeframe during the study
period was deﬁned as the index dose range, and the
ﬁrst day in this 90-day window was identiﬁed as the
index date. Patients were excluded if their highest
mean daily dose was o10 U or 42500 U. Patients
were then grouped based on their index dose range of
10 to 100,4100 to 150,4150 to 200,4200 to 300,
and 4300 to 2500.
Patients identiﬁed as having T2DM were inclu-
ded in the analysis based on the following criteria:
(1) receipt of at least one diagnosis of T2DM in the
1 year before index date (ie, the preindex period) and
no receipt of diagnosis of T1DM in the preindex
period; (2) receipt of at least 2 diagnoses of T2DM in
the preindex period and no more than 1 receipt of
T1DM in the preindex period; or (3) receipt of an oral
antidiabetic in the preindex period. Given that re-
search has found differences in patient outcomes,
costs, and adherence between U-500 insulin users
and high-dose U-100 insulin users,17,18 patients re-
ceiving U-500 insulin were excluded. Females were
also excluded if they were pregnant at any time from
the start of the preindex period through the end of the
postindex period. In addition, patients were required
to have had continuous insurance coverage from the
start of the preindex period through the end of the
postindex period. Finally, given that our database
spanned the time horizon from January 1, 2007,
through December 31, 2011, our 1-year preindex
and 1-year postindex necessitated that the index date
be between January 1, 2008, and January 1, 2011.
These inclusion and exclusion criteria yielded a sample
of 101,728 individuals. Figure 1 illustrates how each
of these criteria affected sample size.
Outcomes of interest were measured during the
1-year postindex date and included costs, resource
use, adherence, and hypoglycemic events. Medical
costs for these analyses were proxied by total gross
payments to all providers who submitted claims for
covered services rendered and were inﬂated to 2011
dollars using the medical component of the Consumer
Price Index.19 Costs were also categorized as all-cause
or diabetes related if they had an accompanying
diagnosis of 250.xx or were for receipt of antidiabetic
medication or diabetic supplies. Within the all-causeVolume 37 Number 10
Receipt of highest mean dose of U-100 insulin between
10 and 2500 U/d
(First date identified as index date)
N=786,949
No use of U-500 insulin during study period
n=782,252
Receipt of at least 2 diagnoses of diabetes during
study period
n=728,310
No diagnosis of pregnancy during study period
n=710,159
Age at least 18 years as of index date
n=677,742
Continuous insurance coverage during study period
n=117,089
Identified with type 2 diabetes
n=101,728
Figure 1. Inclusion and exclusion criteria and sam-
ple size. For the continuous insurance
coverage, the study period is defined as
12 month before the index date through
12 months after the index date.
E.L. Eby et al.and diabetes-related groupings, costs were subdivided
into inpatient, emergency department (ED), outpa-
tient, and drug costs. Resource use included the
number of hospitalizations, ED visits, ofﬁce visits,
and hospital length of stay. Hospitalizations were
categorized as either all-cause or diabetes related (ie,
having an accompanying diagnosis of diabetes). Ad-
herence was proxied by the proportion of days
covered (PDC), deﬁned as the percentage of unique
days in the postindex period during which the indi-
vidual was prescribed insulin at their index dose
range. Finally, hypoglycemia was captured by receipt
of an International Classiﬁcation of Diseases, Ninth
Revision, Clinical Modiﬁcation (ICD-9-CM) diagnostic
code for the.October 2015Multivariable analyses were used to examine the
association between the outcomes of interest and
index insulin dosage. All analyses controlled for the
individual patient’s characteristics (age, sex, region of
residence, insurance coverage at index date, and type
of diabetes), general health status, preindex comor-
bidities, antidiabetic medication use, and resource use.
General health was proxied by the Charlson Comor-
bidity Index.20,21 Preindex comorbid diagnoses of
interest included retinopathy, nephropathy, neuropa-
thy, coronary artery disease, peripheral vascular dis-
ease, coronary heart disease, hypertension, depression,
obesity, and malignancy. The ICD-9-CM diagnostic
codes used for these conditions, as well as all other
conditions used in the study, are given in the Appen-
dix. Medication use during the preindex period
encompassed any prescription ﬁlled for an oral anti-
diabetic agent, a noninsulin injectable, an insulin
pump, or an insulin pen or vial. An indicator variable
for visits to an endocrinologist in the preindex period
was also included.
Means (SDs) for continuous variables and frequen-
cies (percentages) for categorical variables (ie, descrip-
tive statistics) were used to characterize the sample. T
statistics and χ2 statistics were used to test for statisti-
cally signiﬁcant differences between the cohorts. Gen-
eral linear models with a γ-distribution and log link
were used to examine costs. Two-part models were
used to examine inpatient and ED costs, where the
ﬁrst part captured the probability of using the service
and the second part estimated costs among users of
the service. Resource use was examined by estimating
negative binomial regression, whereas logistic regres-
sions analyzed the likelihood of achieving a PDC
threshold of Z0.80 or a hypoglycemic event. All
analyses were conducted using SAS statistical soft-
ware, version 9.3 (SAS Institute, Cary, North Caro-
lina). Po 0.05 was considered statistically signiﬁcant.
RESULTS
Table I presents patient characteristics, based on index
dose range, for the population of 101,728 individuals
who met the inclusion and exclusion criteria. Results
revealed that as the index dose range increased, the
percentage of males increased, and patients were more
likely to reside in the North Central region of the
United States and less likely to reside in the South.
In this study, patients with diabetes were less likely to
reside in the Northeast or Western regions of the2299
Table I. Patient characteristics per dose cohort.*
Characteristic
Dose, U/d
P†
10–100 4100–150 4150–200 4200–300 4300–2500
(n ¼ 63,676) (n ¼ 19,206) (n ¼ 9259) (n ¼ 6861) (n ¼ 2726)
Age, mean (SD), y 53.03 (9.14) 53.25 (9.87) 53.76 (9.54) 54.87 (8.55) 55.20 (7.78) o0.0001
Sex, No. (%) o0.0001
Female 30,537 (47.96) 8870 (46.18) 4103 (44.31) 2924 (42.62) 1105 (40.54)
Male 33,139 (52.04) 10,336 (53.82) 5156 (55.69) 3937 (57.38) 1621 (59.46)
Region, No. (%) o0.0001
Northeast 9108 (14.30) 3043 (15.84) 1356 (14.65) 995 (14.50) 398 (14.60)
North Central 16,365 (25.70) 5623 (29.28) 2814 (30.39) 2150 (31.34) 902 (33.09)
West 10,182 (15.99) 2996 (5.60) 1472 (15.90) 1079 (15.73) 426 (15.63)
South 28,021 (44.01) 7544 (39.28) 3617 (39.06) 263 (38.43) 1000 (36.68)
Insurance, No. (%)‡ o0.0001
HMO 10,476 (16.45) 2890 (15.05) 1292 (13.95) 947 (13.80) 365 (13.39)
POS 5639 (8.86) 1728 (9.00) 861 (9.30) 653 (9.52) 257 (9.43)
Other 11,381 (17.87) 3806 (19.82) 1818 (19.63) 1406 (20.49) 591 (21.68)
PPO 36,180 (56.82) 10,782 (56.14) 5288 (57.11) 3855 (56.19) 1513 (55.50)
Preindex CCI, mean (SD) 2.00 (1.65) 2.23 (1.61) 2.33 (1.66) 2.44 (1.69) 2.62 (1.73) o0.0001
Preindex comorbidities, No. (%)
Retinopathy 6197 (9.73) 2862 (14.90) 1404 (15.16) 1075 (15.67) 456 (16.73) o0.0001
Nephropathy 6208 (9.75) 2123 (11.05) 1109 (11.98) 909 (13.25) 405 (14.86) o0.0001
Neuropathy 2920 (4.59) 1086 (5.65) 575 (6.21) 478 (6.97) 226 (8.29) o0.0001
Coronary artery disease 9417 (14.79) 3347 (17.43) 1764 (19.05) 1520 (22.15) 644 (23.62) o0.0001
Peripheral vascular disease 3388 (5.32) 1155 (6.01) 643 (6.94) 528 (7.70) 219 (8.03) o0.0001
Congestive heart failure 3330 (5.23) 1111 (5.78) 638 (6.89) 524 (7.64) 269 (9.87) o0.0001
Hypertension 36,858 (57.88) 11,297 (58.82) 5667 (61.21) 4507 (65.69) 1869 (68.56) o0.0001
Depression 3855 (6.05) 1195 (6.22) 584 (6.31) 469 (6.84) 213 (7.81) 0.0006
Obesity 6568 (10.31) 2057 (10.71) 1269 (13.71) 1099 (16.02) 579 (21.24) o0.0001
Malignant tumor 3950 (6.20) 1175 (6.12) 571 (6.17) 437 (6.37) 196 (7.19) 0.2795
Preindex visit to endocrinologist, No. (%) 11,095 (17.42) 5057 (26.33) 2668 (28.82) 2155 (31.41) 913 (33.49) o0.0001
CCI ¼ Charlson Comorbidity Index.
*χ2 statistics for categorical variables and analyses of variance for continuous variables.
†P values compare differences across dosage categories.
‡HMO ¼ health maintenance organization; POS ¼ point of service; PPO ¼ preferred provider organization.
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E.L. Eby et al.country. As index dose range increased, the
percentage of patients insured with a health
maintenance organization decreased. In addition, as
the index dose range increased, patient overall health
generally worsened, as evidenced by the higher mean
Charlson Comorbidity Index score and the greater
percentage of individuals diagnosed as having
retinopathy, nephropathy, neuropathy, coronary
artery disease, peripheral vascular disease, congestive
heart failure, hypertension, depression, and obesity.
Patients with a higher index dose range were also
more likely to have visited an endocrinologist in the
preindex period.
Table II gives the antidiabetic medication use,
based on index dose range, both at the index date
and during the preindex period. As the index dosage
increased, patients were most likely to have been
prescribed multiple types of insulin and were less
likely to have been prescribed only basal insulin as
their index medication. In contrast, as dosage
increases, patients were generally less likely to have
been untreated for their diabetes in the preindex
period or to have been treated with a noninsulin
therapy (oral antidiabetic, glucagon-like peptide 1
receptor agonists, or amylin agonist).
Table III gives the association between the index
dose range and total annual direct medical costs.
Results revealed that inpatient and ED costs, both
all-cause and diabetes related, were highest among the
patients with the lowest dose range and highest dose
range. As the index dosage increased, drug costs (both
all-cause and diabetes related) also increased. Likewise,
both all-cause outpatient and total costs, as well as
diabetes-related outpatient costs and diabetes-related
total costs, increased as index dosage increased.
Table IV presents the differences in annual resource
use associated with index insulin use. In general, these
results are consistent with the cost results presented in
Table III. For example, the lowest-dose-range and
highest-dose-range cohorts had the highest number of
all-cause hospitalizations, diabetes-related hospitaliza-
tions, and ED visits, as well as the longest all-cause
hospital length of stay. These results were generally
consistent whether examining all patients or only
patients who used the service of interest. Among all
patients, ofﬁce visits increased as index dose range
increased.
Figures 2 and 3, respectively, examine the proba-
bility of achieving a PDC threshold of at least 0.80 atOctober 2015the index dose range or having a hypoglycemic event
in the postindex period. Results revealed that, com-
pared with patients with an index dose of 10 to 100
U/d, those who received a higher index dose range
were signiﬁcantly less likely to achieve a PDC thresh-
old of at least 0.80. The 2 middle-range dosing
cohorts had similar odds of achieving the PDC thresh-
old: patients with an index dose4150 to 200 U/d had
a 91% reduction in the likelihood of achieving a
threshold of 0.80 (odds ratio [OR] = 0.089; 95% CI,
0.079–0.101), whereas those with an index dose
4200 to 300 were 92% less likely to achieve this
threshold (OR = 0.075; 95% CI, 0.065–0.088).
Patients in the highest dose range (4300 U/d) had
an 82% reduction in the likelihood of achieving the
PDC threshold relative to the lowest-dose-range co-
hort (OR = 0.181; 95% CI, 0.154–0.213). Figure 3
illustrates that there was no statistically signiﬁcant
association between index insulin dose range and the
probability of a hypoglycemic event in the postindex
period.
Finally, we brieﬂy examined differences within the
lowest dose cohort by subdividing the group based on
receipt of oral antidiabetic medications (0, 1, 2, or
Z3). The results (not reported) indicated that both all-
cause and diabetes-related inpatient, outpatient, and
ED costs generally decreased as the number of anti-
diabetic medications increased. Furthermore, the num-
ber of hospitalization, hospital length of stay, and
number of ED visits generally followed the same
pattern. Patients who received 10 to 100 U/d of
insulin and 1 or 2 oral antidiabetic medications were
also found to be signiﬁcantly less likely to have a
hypoglycemic event compared with those treated with
the same dosage of insulin who did not receive any
oral antidiabetic medications.
DISCUSSION
This study examined the association between insulin
dosing outcomes, such as costs, resource use, and
adherence, and hypoglycemic events. The main results
of this study revealed statistically signiﬁcant associa-
tions between insulin dosing and speciﬁc patient
characteristics, as well as among dosing, costs, and
resource use.
In this study, total direct medical costs and resource
use generally tended to increase as insulin dosage
increased. Although the highest-dose-range patients
in this study were relatively few in number (2726 of2301
Table II. Antidiabetic medication use based on index dose range at the index date and during the preindex period.*
Dose, U/d
Variable 10–100 (n ¼ 63,676) 4100–150 4150–200 4200–300 4300–2500 P†
Index medication o.0001
Basal 35,054 (55.05) 4751 (24.74) 1520 (16.42) 853 12.43 222 8.14
Basal and bolus 13,801 (21.67) 8092 (42.13) 4791 (51.74) 4088 59.58 1854 68.01
Basal, bolus, and premix 179 (0.28) 142 (0.74) 104 (1.12) 127 1.85 66 2.42
Basal and premix 652 (1.02) 419 (2.18) 246 (2.66) 219 3.19 88 3.23
Bolus 7153 (11.23) 3219 (16.76) 1373 (14.83) 739 10.77 215 7.89
Bolus and premix 338 (0.53) 272 (1.42) 141 (1.52) 139 2.03 76 2.79
Premix 6499 (10.21) 2311 (12.03) 1084 (11.71) 696 10.14 205 7.52
Preindex diabetic medication use‡
Basal 35,370 (55.55) 14,098 (73.40) 7088 (76.55) 5542 (80.78) 2322 (85.18) o.0001
Bolus 15,017 (23.58) 12,058 (62.78) 6626 (71.56) 5282 (76.99) 2310 (84.74) o.0001
Premix 6097 (9.58) 3378 (17.59) 1785 (19.28) 1385 (20.19) 502 (18.42) o.0001
Human 6431 (10.10) 3321 (17.29) 1816 (19.61) 1452 (21.16) 586 (21.50) o.0001
Analog 39,305 (61.73) 16,914 (88.07) 8312 (89.77) 6212 (90.54) 2518 (92.37) o.0001
Pen 23,024 (36.16) 9686 (50.43) 4888 (52.79) 3663 (53.39) 1522 (55.83) o.0001
Vial 24,779 (38.91) 12,309 (64.09) 6157 (66.50) 4763 (69.42) 1941 (71.20) o.0001
Pump 3815 (5.99) 2764 (14.39) 1214 (13.11) 737 (10.74) 225 (8.25) o.0001
Insulin 43,496 (68.31) 18,561 (96.64) 9079 (98.06) 6785 (98.89) 2696 (98.90) o.0001
Oral 41,810 (65.66) 10,334 (53.81) 5056 (54.61) 3952 (57.60) 1555 (57.04) o.0001
No. of oral agents, mean (SD) 1.19 (1.09) 0.88 (0.99) 0.84 (0.94) 0.87 (0.92) 0.81 (0.87) o.0001
GLP/amylin 4958 (7.79) 1509 (7.86) 768 (8.29) 662 (9.65) 292 (10.71) o.0001
Diabetic medication use o.0001
Insulin and oral/GLP-amylin 29,797 (46.79) 10,295 (53.60) 5142 (55.54) 4078 (59.44) 1645 (60.34)
Insulin only 13,699 (21.51) 8266 (43.04) 3937 (42.52) 2707 (39.45) 1051 (38.55)
None 7763 (12.19) 342 (1.78) 107 (1.16) 46 (0.67) 20 (0.73)
Oral/GLP-1 RA/amylin analog 12,417 (19.50) 303 (1.58) 73 (0.79) 30 (0.44) 10 (0.37)
GLP-1 ¼ glucagon-like peptide 1; RA ¼ receptor agonist.
*Data are presented as number (percentage) of patients unless otherwise indicated. χ2 statistics for categorical variables and analyses of variance for continuous
variables.
†P values compare differences across dosage categories.
‡Preindex diabetic medication use deﬁned as medications used in the 1 year before the index date.
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October 2015101,728), they had the highest inpatient and ED-
related costs and resource use in addition to having
the highest drug costs and total costs. Such a ﬁnding
is consistent with the previous literature, which
found that total direct medical costs tended to
increase as insulin use and drug costs increased.22
However, in this study, total diabetes-related direct
medical costs ranged from $8079 to $17,681. This
estimate is substantially lower than estimates pro-
vided by the American Diabetes Association for
individuals aged o65 years.4 Such a difference may
be because this analysis focuses exclusively on an
insured cohort of T2DM patients treated with
insulin.
Patients requiring 4200 U/d of exogenous insulin
are considered to have severe insulin resistance,23 and
previous literature has noted a reluctance on the part
of patients and clinicians to use very high doses of
U-100 insulin to adequately treat highly insulin-
resistant patients.24 Highly insulin-resistant patients
also have a reduced physiologic response to high
volumes of U-100 insulin.24 A meta-analysis of the
use of U-500R insulin by multiple daily injections
found that the use of such insulin was associated with
a 1.59% reduction in HbA1c.
25 The present ﬁndings
indicate signiﬁcant economic and humanistic incen-
tives for any improvement in the outcomes of this
small but costly subgroup.
One exception to the general trend of costs and
resource use increasing as index dose range increased
was that the lowest-dose-range cohort did not have
the lowest total direct medical costs despite using less
insulin than the other patients. In addition, this cohort
had costs comparable to the high-dose cohort for the
categories of diabetes-related and all-cause inpatient
and ED costs. These ﬁndings suggest there may be
potential beneﬁts of more intensive insulin treatment
among this cohort.
In previous studies, medication adherence has been
found to be the single factor with the greatest effect on
treatment costs.26,27 In the present study, patients
taking the lowest dose of insulin (index range, 10–
100 U/d) were more likely to adhere to their insulin
regimen (ie, to achieve a PDC threshold of at least
80%) relative to patients on any of the higher dose
ranges. In addition, with the exception of the highest
index range, adherence generally decreased as the
insulin doses increased, consistent with earlier reports
that adherence to antidiabetic therapies tends to2303
Table IV. Mean (SD) resource use and index dose in all patients.*
Resource Use
Dose, U/d
10–100 4100–150 4150–200 4200–300 4300–2500 P
All patients
Hospital, LOS, d 2.73 (6.23) 2.01 (3.24) 2.21 (3.98) 2.67 (4.64) 3.39 (7.70) o0.0001
No. of hospitalizations 0.39 (0.49) 0.29 (0.30) 0.31 (0.34) 0.34 (0.37) 0.44 (0.53) o0.0001
No. of ED visits 0.78 (0.67) 0.68 (0.53) 0.72 (0.56) 0.73 (0.62) 0.86 (0.71) o0.0001
No. of ofﬁce visits 12.93 (4.75) 14.05 (5.17) 14.93 (5.52) 16.47 (6.33) 17.80 (6.47) o0.0001
Diabetes-related hospital LOS, d 1.71 (3.35) 1.28 (1.88) 1.37 (2.15) 1.62 (2.66) 2.18 (4.03) o0.0001
No. of diabetes–related hospitalization 0.27 (0.31) 0.21 (0.20) 0.21 (0.21) 0.23 (0.24) 0.29 (0.31) o0.0001
Users of resource only
Hospital LOS, d 10.66 (4.37) 10.30 (4.09) 10.33 (4.34) 10.79 (4.50) 11.25 (4.66) o0.0001
No. of hospitalizations 1.61 (0.35) 1.61 (0.35) 1.52 (0.34) 1.55 (0.36) 1.59 (0.35) o0.0001
No. of ED visits 2.25 (0.69) 2.22 (0.68) 2.16 (0.65) 2.17 (0.70) 2.39 (0.73) o0.0001
Diabetes-related hospital LOS, d 8.53 (3.03) 8.60 (2.99) 8.64 (3.03) 9.00 (3.31) 10.33 (3.65) o0.0001
No. of diabetes-related hospitalizations 1.42 (0.27) 1.47 (0.28) 1.40 (0.27) 1.41 (0.29) 1.50 (0.27) o0.0001
ED ¼ emergency department; LOS ¼ length of stay.
*Negative binomial regressions controlling for patient characteristics (age, sex, region of residence, and insurance coverage), preperiod general health and
comorbidities (Charlson Comorbidity Index, retinopathy, nephropathy, neuropathy, coronary artery disease, peripheral vascular disease, congestive heart failure,
hypertension, depression, obesity, and malignant tumor), preperiod antidiabetic medication use (oral, insulin, noninsulin injectable, pump, and vial), and preperiod
visit to an endocrinologist. Inpatient and ED costs were estimated using 2-part models. P values compare differences across dosage categories.
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Figure 2. Probability of proportion of days covered Z0.80. Results from logistic regression that controls
for patient characteristics, preperiod comorbidities, preperiod general health, preperiod use
of antidiabetic medications, preperiod visit to endocrinologist, and index dose (reference dose,
10–100 U/d).
E.L. Eby et al.decrease as treatment complexity increases.27–29 How-
ever, such a decrease in adherence may be due to
prescribed insulin adjustment by patients, which
cannot be directly measured in the study database.
Previous research has also found that among patients
taking high-dose U-100 insulin (4150 or4200 U/d),
adherence can be improved by switching to U-500
insulin.18,30 These results emphasize the importance ofInsulin 
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October 2015using strategies to mitigate the complexity of anti-
diabetic treatment regimens wherever possible.
Hypoglycemic events are a serious potential con-
sequence of insulin therapy and have been linked to
signiﬁcant humanistic and economic costs.31 A large
body of literature has reported that intensive insulin
therapy (ie, therapy designed to reduce glycemia to an
HbA1c level of r7%) is associated with a higher rateDose, U/d
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from logistic regression that controls for patient
eriod general health, preperiod use of antidiabetic
t, and index dose (reference dose, 10–100 U/d).
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Clinical Therapeuticsof severe hypoglycemia relative to less aggressive
insulin treatment.31–35 In contrast to this literature,
the present study revealed no statistically signiﬁcant
association between daily insulin dosage and the
probability of a hypoglycemic event. However, this
study focuses on hypoglycemic events that were severe
enough for a patient to have a physician, ED, or
hospital visit with an accompanying diagnosis of
hypoglycemia.
Results of this study must be interpreted within the
context of the study limitations. First, these analyses
were based on observational health insurance claims
data of individuals aged o65 years, which may limit
the generalizability of the results. Second, the use of
diagnostic codes is not as rigorous as formal assess-
ments and may underrepresent certain conditions or
events (eg, obesity, hypoglycemia). Furthermore, costs
classiﬁed as diabetes-related based on receipt of a
diagnosis of diabetes or receipt of an antidiabetic
medication may overstate the costs associated with
treatment of diabetes because patients are generally
not treated for one condition in isolation. Third, our
data collection did not allow for an examination of
the speciﬁc reason why patients were visiting the
hospital or ED unless such a visit was associated with
a diagnosis of diabetes. Fourth, the use of claims data
precluded an examination of associations between
outcomes and nondocumented factors, such as race,
socioeconomic class, body mass index, HbA1c, or
duration of diabetes. Fifth, the methods precluded
observation of the manner in which the insulin was
self-administered (eg, whether or how the individual
patient may have self-adjusted the dosing) and any
related effects. In addition, the analyses controlled for
type of insurance coverage as of the index date and do
not reﬂect any changes in insurance status. Finally, the
analysis focused on statistical signiﬁcant associations
and, hence, was unable to determine whether differ-
ences in outcomes represented minimal clinically
important changes or if any such changes are due to
causation.
CONCLUSIONS
In this study of insulin dosing among US patients
diagnosed as having T2DM, the largest cohort (63%
of the population) consisted of individuals on the
lowest mean daily dose (10–100 U/d) of insulin,
whereas the smallest cohort (2.7%) comprised those
patients taking the largest mean daily dose (4300 U/d).2306These 2 cohorts were found to have the highest res-
ource use and the largest all-cause and diabetes-related
inpatient and ED costs. Adherence, as measured by
the PDC in the index dose range, generally decreased
as index dose range increased, although the analyses
found no association between index dosage and the
probability of a hypoglycemic event. The results of
this study suggest that physicians may want to pay
careful attention to patients receiving relatively low
insulin doses and to consider alternative dosing
regimens (eg, U-500) for patients who receive high
mean daily doses of U-100 insulin.
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E.L. Eby et al.SUPPLEMENTARY MATERIALTable A1. Diagnostic codes.
Diabetes and Comorbidities ICD-9-CM Diagnostic Codes
Diabetes 250.xx
Type 1 diabetes 250.x1; 250.x3
Type 2 diabetes 250.x0; 250.x2
Pregnancy 630.xx-679.xx; V22.xx-V24.xx; V27.xx, V29.xx
Retinopathy 362.01 – 362.06
Nephropathy 403.xx; 404.xx; 583.81; 585.xx – 586.xx except 585.6;
Neuropathy 354.xx; 355.xx; 249.6 or 250.6 in conjunction with 357.2 or 337.1
Coronary artery disease 410.xx – 414.xx
Peripheral vascular disease 440.xx; 443.81; 443.89; 443.9;
Congestive heart failure 402.01; 402.11; 402.91; 404.01; 404.03; 404.11; 404.13; 404.91; 404.92; 428.xx
Hypertension 401.xx – 405.xx
Depression 296.2; 296.3; 300.4; 311.xx
Obesity 278.xx except 278.02; V853.x; V854
Malignant tumor 140.xx – 209.xx
Hypoglycemia 251.0x-251.2x, 270.3x, 775.0x, 775.6x, 962.3x
ICD-9-CM ¼ International Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation.October 2015 2308.e1
